Work

Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.6_suppl.272

Authors: Toni K. Choueiri, Todd Michael Bauer, David F. McDermott, Edward Arrowsmith, Ananya Roy, Rodolfo F. Perini, Donna Vickery, Scott S. Tykodi

Institutions: Dana-Farber Cancer Institute, Sarah Cannon, Tennessee Oncology, Beth Israel Deaconess Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States), University of Washington

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4206799448

Cites:

Cited by: 31

Related to: 10